Görüntüleme
11
İndirme
2
Amaç: Meme kanseri kadınlarda en sık görülen ve en sık ölüme neden olan kanserdir. Biz de merkezimizde takip ettiğimiz metastatik meme kanseri (MMK) olan hastaların klinik özelliklerini ve tedavi sonuçlarını araştırmak istedik. Gereç ve Yöntemler: Çukurova Üniversitesi Onkoloji bilim dalında 2011-2017 yılları arasında takip edilen 65 MMK olan hasta çalışmaya dahil edildi. Hastaların klinik özellikleri ve aldıkları tedaviler retrospektif olarak araştırıldı. Bulgular: Hastaların büyük çoğunluğunda sadece kemik metastazı vardı. Sonradan metastatik evreye geçen 45 hastanın %66,6’ sına yeniden biyopsi yapıldı bu hastaların %20’ sinde tümör biyolojisi değişmişti. Metastatik evrede progresyonsuz sağkalım 10 ay, ortalama sağkalım 34 ay olarak hesaplandı. Tartışma ve Sonuç: MMK olan hastalarda literatürle uyumlu sağkalımlar elde edilmiştir. Yeni kullanıma giren ajanlar ve hedefleyici tedavilerdeki gelişmeler de göz önüne alındığında hastalık biyolojisindeki değişme ihtimali göz önünde bulundurularak relapslarda yeniden biyopsi yapılması kritik önemdedir.
Objective: Breast cancer is a cancer that causes death in women. We also wanted to investigate the clinical characteristics and treatment results of patients with metastatic breast cancer (MMK) we followed in our center. Tools and Methods: The University of Çukurova was included in the study of patients with 65 MMK followed between 2011-2017 years in the oncology science. The clinical characteristics of the patients and the treatments they received were examined retrospectively. The majority of patients had only bone metastases. 66.6 percent of 45 patients who went to the subsequent metastatic stage were re-biopsied; 20 percent of these patients had a change in the tumor biology. In the metastatic stage, progressive survival was calculated for 10 months, the average survival was 34 months. Discussions and Results: Patients with MMK have obtained consistent survival with literature. Having regard to the newly used agents and the developments in targeting treatments, it is critical to re-biopsy in recurrences, taking into account the possibility of change in the disease biology.
Aim: Breast cancer is the most common cancer that causes death in women. We wanted to investigate the clinical features and treatment results of patients with metastatic breast cancer. Materials and Methods: Sixty-five patients with metastatic breast cancer followed in the Oncology Department of Cukurova University between 2011 and 2017 were included in the study. The clinical features and treatments of the patients were investigated retrospectively. Results: The majority of patients had only bone metastases. Re-biopsy was performed in 66,6% of 45 patients who subsequently underwent metastatic stage; and tumor biology had changed in 20% of these patients. The progression-free survival in the metastatic stage was 10 months and the overall survival was 34 months. Discussion and Conclusion: Survival of patients with metastatic breast cancer is consistent with the literature. When new agents and new therapies are also taken into consideration, re-biopsy at relapses is critical in considering the possibility of changes in disease biology.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Makale Detay 
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Alıntı Yap
Bu Sayfayı Yazdırın
Paylaş
Mendeley
